secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sonoma Pharmaceuticals, Inc. (SNOA)
CIK:        0001367083
Form:       8-K
Filed at:   2023-01-31T23:59:59+00:00
Accession:  0001683168-23-000420
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sonoma enters exclusive South Korea distribution deal with Daewoong for Primocyn
--------------------------------------------------------------------------------

- Exclusive distribution agreement effective Jan 26, 2023 for Primocyn Skin Solution (Microcyn technology) in South Korea.
- Initial term of two years, automatically renewing for two-year periods unless terminated.
- Daewoong responsible for obtaining marketing authorization and all regulatory clearances in the territory.
- Minimum purchase thresholds (redacted) required to maintain exclusivity beyond second year; initial fee also redacted.
- Sonoma to provide registration dossier within 90 days; Daewoong to apply for marketing authorization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367083/000168316823000420/0001683168-23-000420-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367083/000168316823000420/sonoma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-000420

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer